

### Precision Supports the Gynecologic Cancer Awareness Movement!

Precision was one of many companies who supported the 2010 *Foundation for Women's Cancer Walk* in Washington D.C. on November 6<sup>th</sup>. For more info, please visit [www.foundationforwomenscancer.org](http://www.foundationforwomenscancer.org).

### Precision Presents Abstract at AAPS

Precision recently presented an abstract at the American Association of Pharmaceutical Scientists (AAPS) annual meeting held in Washington D.C. on October 23-27, that illustrates the complementary nature of the ChemoF<sub>x</sub> PRO<sup>®</sup> study to the National Cancer Institute's Cancer Genome Atlas (NCI-TCGA):

#### Opportunities for the Advancement of Personalized Medicine: The NCI-TCGA and Complementary Resources in the ChemoF<sub>x</sub> PRO<sup>®</sup> Study

\*1,081 patients with ovarian cancer have been enrolled in ChemoF<sub>x</sub> PRO<sup>®</sup>.

\*49% (527) of those were primary serous adenocarcinoma, and are similar to the ovarian cancer patient population included in the NCI-TCGA.

\*Both NCI-TCGA and ChemoF<sub>x</sub> PRO<sup>®</sup> included frozen specimens for genomic and proteomic testing. There were many similarities between the PRO<sup>®</sup> patient set and the NCI-TCGA. Therefore, the specimens, in combination with additional clinical data included in ChemoF<sub>x</sub> PRO<sup>®</sup> may be useful for identifying additional molecular and cellular markers that have the potential to result in more accurate prognostic, diagnostic and treatment strategies for cancer patients. ‡

### One of Pittsburgh's Fastest Growing Companies!

*Inc. Magazine* recognized Precision as one of the top 500 fastest growing private companies in the US. Precision is also one of the fastest growing companies in Pittsburgh, as determined by the *Pittsburgh Business Times' Pittsburgh 100* list. Please visit [www.chemofx.com](http://www.chemofx.com) to view our press releases on both awards.



## What we do.

Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.

### Precision Hosts Multigene Lung Signature Ad Board in Amsterdam

Key opinion leaders in lung cancer treatment from around the globe gathered for the *Precision Therapeutics' Working Group on Molecular Signatures* advisory panel following the conclusion of the 14<sup>th</sup> Annual World Conference on Lung Cancer. The group provided guidance and reviewed the challenges behind commercialization and validation of Precision's new multigene lung signature.

Using gene expression profiles from patients randomized to the observation arm of JBR.10, Drs. Frances Shepherd, Ming Tsao and colleagues identified a gene signature that was both prognostic and predictive for survival benefit from chemotherapy in patients with early stage non-small cell lung cancer (NSCLC). This gene signature was validated using 4 independent published microarray data sets comprising gene expression profiles of tumors from patients with completely resected stage IB to II NSCLC who did not receive any adjuvant chemotherapy.

The consensus of the Working Group was that this was the optimal signature available because of the scientifically rigorous approach used to identify the signature. The use of samples from prospectively recruited patients and validation via multiple independent datasets generated much enthusiasm for the potential commercialization of the multigene signature for use in NSCLC.

Precision held an additional advisory panel on October 6<sup>th</sup> in Boston, MA prior to the start of the 3<sup>rd</sup> Biennial Minimally Invasive Thoracic Summit with a group of thoracic surgeons who also reviewed and discussed the commercialization of the gene lung signature. More information on the progress of this signature will be available in the next issue of the *Precision Post*.

### Metachronous Pair Abstract Presented at ESGO<sup>†</sup>

Dr. James Fiorica recently presented data at the European Society of Gynecologic Oncology (ESGO) annual meeting that examined changes in ChemoF<sub>x</sub> results from primary diagnosis to recurrent disease in gynecologic tumors with intervening administration of chemotherapy. Researchers identified 36 patients from the ChemoF<sub>x</sub> PRO<sup>®</sup> study as having received ChemoF<sub>x</sub> test results at both diagnosis and upon recurrence of disease, with results at least 90 days apart. All 36 patients were also administered intervening adjuvant platinum/taxane therapy. Changes in chemoresponse were evaluated across a number of drugs and drug combinations including carboplatin, docetaxel, doxorubicin, gemcitabine, paclitaxel, and carboplatin/paclitaxel. No statistically significant shifts in ChemoF<sub>x</sub> results were observed between the primary and recurrent tumor testing, suggesting that in vitro chemoresponse is relatively stable across the course of disease. This supports the use of ChemoF<sub>x</sub> results obtained in the primary setting to inform treatment strategy in the recurrent setting. For more information, please contact your Clinical Oncology Specialist.

\*Cancer Biology & Therapy 11:12, 1059-1064; June 15, 2011.

†J. Fiorica et al. 17<sup>th</sup> International Meeting of ESGO; Sept. 11-14, 2011.

‡C. McClure, Ma, H., Kim, S. AAPS Annual Meeting and Exposition Abstract #T3396; October 23-27, 2011.

[www.chemofx.com](http://www.chemofx.com) • [info@precisiontherapeutics.com](mailto:info@precisiontherapeutics.com) • 1-800-547-6165

Precision Therapeutics is a CLIA-certified clinical laboratory